Viral polymerase-helicase complexes regulate replication fidelity to overcome intracellular nucleotide depletion

Journal of Virology

Volumn 89, Issue 22, 2015, Pages 11233-11244

  Stapleford, Kenneth A ^a   Rozen Gagnon, Kathryn ^a   Das, Pratyush Kumar ^b,c   Saul, Sirle ^b   Poirier, Enzo Z ^a   Blanc, Hervé ^a   Vidalain, Pierre Olivier ^a,d,e   Merits, Andres ^b   Vignuzzi, Marco ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY OF TARTU   (Estonia)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 2; NSP4 PROTEIN; NUCLEOTIDE; PURINE; PYRIMIDINE; RIBAVIRIN; RNA HELICASE; RNA POLYMERASE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CYSTEINE PROTEINASE; NSP2 PROTEINASE; NSP4 SERINE PROTEASE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA DIRECTED RNA POLYMERASE; SERINE PROTEINASE; VIRUS RNA;

ALPHAVIRUS; ANTIVIRAL RESISTANCE; ARTICLE; BIOSYNTHESIS; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME KINETICS; ENZYME PURIFICATION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN POLYMERIZATION; REGULATORY MECHANISM; VIROGENESIS; VIRUS REPLICATION; VIRUS RESISTANCE; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; DEFICIENCY; DNA REPLICATION; DRUG EFFECTS; GENETICS; HAMSTER; HELA CELL LINE; HUMAN; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SEQUENCE ANALYSIS; VERO CELL LINE;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; CHIKUNGUNYA VIRUS; CRICETINAE; CYSTEINE ENDOPEPTIDASES; DNA REPLICATION; HELA CELLS; HUMANS; MUTATION; NUCLEOTIDES; PURINES; PYRIMIDINES; RIBAVIRIN; RNA HELICASES; RNA REPLICASE; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; SERINE ENDOPEPTIDASES; VERO CELLS; VIRUS REPLICATION;

EID: 84945893406     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01553-15     Document Type: Article

References (46)

1. Zeng J, Wang H, Xie X, Li C, Zhou G, Yang D, Yu L. 2014. Ribavirinresistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence. J Virol 159:2641-2650. http://dx.doi.org/10.1007/s00705-014-2126-z.
2. Arias A, Arnold JJ, Sierra M, Smidansky ED, Domingo E, Cameron CE. 2008. Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J Virol 82: 12346-12355. http://dx.doi.org/10.1128/JVI.01297-08.
3. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 100:7289-7294. http://dx.doi.org/10.1073/pnas.1232294100.
4. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2005. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348.
5. Levi LI, Gnädig NF, Beaucourt S, McPherson MJ, Baron B, Arnold JJ, Vignuzzi M. 2010. Fidelity variants of RNA-dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog 6:e1001163. http://dx.doi.org/10.1371/journal.ppat.1001163.
6. Gnädig NF, Beaucourt S, Campagnola G, Bordería AV, Sanz-Ramos M, Gong P, Blanc H, Peersen OB, Vignuzzi M. 2012. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A 109: E2294-E2303. http://dx.doi.org/10.1073/pnas.1204022109.
7. Cheung PPH, Watson SJ, Choy K-T, Fun Sia S, Wong DDY, Poon LLM, Kellam P, Guan Y, Malik Peiris JS, Yen H-L. 2014. Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun 5:4794. http://dx.doi.org/10.1038/ncomms5794.
8. Sadeghipour S, Bek EJ, McMinn PC. 2013. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J Virol 87:1759-1769. http://dx.doi.org/10.1128/JVI.02139-12.
9. Meng T, Kwang J. 2014. Attenuation of human enterovirus 71 highreplication-fidelity variants in AG129 mice. J Virol 88:5803-5815. http://dx.doi.org/10.1128/JVI.00289-14.
10. Coffey LL, Beeharry Y, Bordería AV, Blanc H, Vignuzzi M. 2011. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci U S A 108:16038-16043. http://dx.doi.org/10.1073/pnas.1111650108.
11. Rozen-Gagnon K, Stapleford KA, Mongelli V, Blanc H, Failloux A-B, Saleh M-C, Vignuzzi M. 2014. Alphavirus mutator variants present hostspecific defects and attenuation in mammalian and insect models. PLoS Pathog 10:e1003877. http://dx.doi.org/10.1371/journal.ppat.1003877.
12. Crotty S, Andino R. 2002. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect 4:1301-1307. http://dx.doi.org/10.1016/S1286-4579(02)00008-4.
13. Beaucourt S, Vignuzzi M. 2014. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation: molecular basis of ribavirin resistance. Curr Opin Virol 8:10-15. http://dx.doi.org/10.1016/j.coviro.2014.04.011.
14. Wray SK, Gilbert BE, Knight V. 1985. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antivir Res 5:39-48. http://dx.doi.org/10.1016/0166-3542(85)90013-0.
15. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79:1943-1947. http://dx.doi.org/10.1128/JVI.79.3.1943-1947.2005.
16. Longley DB, Harkin DP, Johnston PG. 2003. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338. http://dx.doi.org/10.1038/nrc1074.
17. Solignat M, Gay B, Higgs S, Briant L, Devaux C. 2009. Replication cycle of Chikungunya: a re-emerging arbovirus. Virology 393:183-197. http://dx.doi.org/10.1016/j.virol.2009.07.024.
18. Ahola T, Kääriäinen L. 1995. Reaction in alphavirus mRNA capping: formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP. Proc Natl Acad Sci U S A 92:507-511. http://dx.doi.org/10.1073/pnas.92.2.507.
19. Karpe YA, Aher PP, Lole KS. 2011. NTPase and 5'-RNA triphosphatase activities of Chikungunya virus nsP2 protein. PLoS One 6:e22336. http://dx.doi.org/10.1371/journal.pone.0022336.
20. Bourai M, Lucas-Hourani M, Gad HH, Drosten C, Jacob Y, Tafforeau L, Cassonnet P, Jones LM, Judith D, Couderc T, Lecuit M, Andre P, Kummerer BM, Lotteau V, Despres P, Tangy F, Vidalain PO. 2012. Mapping of Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component. J Virol 86:3121-3134. http://dx.doi.org/10.1128/JVI.06390-11.
21. Utt A, Das PK, Varjak M, Lulla V, Lulla A, Merits A. 2015. Mutations conferring a noncytotoxic phenotype on Chikungunya virus replicons compromise enzymatic properties of nonstructural protein 2. J Virol 89: 3145-3162. http://dx.doi.org/10.1128/JVI.03213-14.
22. Fros JJ, van der Maten E, Vlak JM, Pijlman GP. 2013. The C-terminal domain of Chikungunya virus nsP2 independently governs viral RNA replication, cytopathicity, and inhibition of interferon signaling. J Virol 87:10394-10400. http://dx.doi.org/10.1128/JVI.00884-13.
23. Fros JJ, Fros JJ, Major LD, Major LD, Scholte FEM, Scholte FEM, Gardner J, Gardner J, van Hemert MJ, van Hemert MJ, Suhrbier A, Suhrbier A, Pijlman GP, Pijlman GP. 2015. Chikungunya virus nonstructural protein 2-mediated host shut-offdisables the unfolded protein response. J Gen Virol 96:580-589. http://dx.doi.org/10.1099/vir.0.071845-0.
24. Fros JJ, Liu WJ, Prow NA, Geertsema C, Ligtenberg M, Vanlandingham DL, Schnettler E, Vlak JM, Suhrbier A, Khromykh AA, Pijlman GP. 2010. Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J Virol 84:10877-10887. http://dx.doi.org/10.1128/JVI.00949-10.
25. Rathore APS, Haystead T, Das PK, Merits A, Ng M-L, Vasudevan SG. 2014. Chikungunya virus nsP3 and nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. Antivir Res 103:7-16. http://dx.doi.org/10.1016/j.antiviral.2013.12.010.
26. McKnight KL, Simpson DA, Lin SC, Knott TA, Polo JM, Pence DF, Johannsen DB, Heidner HW, Davis NL, Johnston RE. 1996. Deduced consensus sequence of Sindbis virus strain AR339: mutations contained in laboratory strains which affect cell culture and in vivo phenotypes. J Virol 70:1981-1989.
27. Beaucourt S, Borderia AV, Coffey LL, Gnadig NF, Sanz-Ramos M, Beeharry Y, Vignuzzi M. 2011. Isolation of fidelity variants of RNA viruses and characterization of virus mutation frequency. J Vis Exp 52: pii2953. http://dx.doi.org/10.3791/2953.
28. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754-1760. http://dx.doi.org/10.1093/bioinformatics/btp324.
29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Subgroup 1GPDP. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078-2079. http://dx.doi.org/10.1093/bioinformatics/btp352.
30. Isakov O, Bordería AV, Golan D, Hamenahem A, Celniker G, Yoffe L, Blanc H, Vignuzzi M, Shomron N. 2015. Deep sequencing analysis of viral infection and evolution allows rapid and detailed characterization of viral mutant spectrum. Bioinformatics 31:2141-2150. http://dx.doi.org/10.1093/bioinformatics/btv101.
31. Lanciotti RS, Kosoy OL, Laven JJ, Panella AJ, Velez JO, Lambert AJ, Campbell GL. 2007. Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis 13:764-767. http://dx.doi.org/10.3201/eid1305.070015.
32. Coffey LL, Vignuzzi M. 2011. Host alternation of Chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures. J Virol 85:1025-1035. http://dx.doi.org/10.1128/JVI.01918-10.
33. Das PK, Merits A, Lulla A. 2014. Functional cross-talk between distant domains of Chikungunya virus non-structural protein 2 is decisive for its RNA-modulating activity. J Biol Chem 289:5635-5653. http://dx.doi.org/10.1074/jbc. M113.503433.
34. Matayoshi ED, Wang GT, Krafft GA, Erickson J. 1990. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247:954-958. http://dx.doi.org/10.1126/science.2106161.
35. Sawicki DL, Perri S, Polo JM, Sawicki SG. 2006. Role for nsP2 proteins in the cessation of alphavirus minus-strand synthesis by host cells. J Virol 80:360-371. http://dx.doi.org/10.1128/JVI.80.1.360-371.2006.
36. Russo AT, Malmstrom RD, White MA, Watowich SJ. 2010. Structural basis for substrate specificity of alphavirus nsP2 proteases. J Mol Graphics Model 29:46-53. http://dx.doi.org/10.1016/j.jmgm.2010.04.005.
37. Russo AT, White MA, Watowich SJ. 2006. The crystal structure of the Venezuelan equine encephalitis alphavirus nsP2 protease. Structure 14: 1449-1458. http://dx.doi.org/10.1016/j.str.2006.07.010.
38. Lucas-Hourani M, Dauzonne D, Jorda P, Cousin G, Lupan A, Helynck O, Caignard G, Janvier G, André-Leroux G, Khiar S, Escriou N, Després P, Jacob Y, Munier-Lehmann H, Tangy F, Vidalain P-O. 2013. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 9:e1003678. http://dx.doi.org/10.1371/journal.ppat.1003678.
39. Cholewiński G, Iwaszkiewicz-Grzes D, Prejs M, Glowacka A, Dzierzbicka K. 2015. Synthesis of the inosine 5Ø-monophosphate dehydrogenase (IMPDH) inhibitors. J Enzyme Inhibition Med Chem 30:550-563. http://dx.doi.org/10.3109/14756366.2014.951349.
40. Scheidel LM, Durbin RK, Stollar V. 1987. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158:1-7. http://dx.doi.org/10.1016/0042-6822(87)90230-3.
41. Smith EC, Blanc H, Vignuzzi M, Denison MR. 2013. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 9:e1003565. http://dx.doi.org/10.1371/journal.ppat.1003565.
42. Smith EC, Case JB, Blanc H, Isakov O, Shomron N, Vignuzzi M, Denison MR. 2015. Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelity. J Virol 89:6418-6426. http://dx.doi.org/10.1128/JVI.00110-15.
43. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. 2012. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 18:1820-1826. http://dx.doi.org/10.1038/nm.2972.
44. Campagnola G, McDonald S, Beaucourt S, Vignuzzi M, Peersen OB. 2014. Structure-function relationships underlying the replication fidelity of viral RNA-dependent RNA polymerases. J Virol 89:275-286. http://dx.doi.org/10.1128/JVI.01574-14.
45. Airaksinen A. 2003. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311:339-349. http://dx.doi.org/10.1016/S0042-6822(03)00144-2.
46. Koonin EV. 1991. Similarities in RNA helicases. Nature 352:290-290. http://dx.doi.org/10.1038/352290b0.